Evidence map›Paper›PMID 29950420›Full record

ArticleJournal of virology2018

25-Hydroxycholesterol Production by the Cholesterol-25-Hydroxylase Interferon-Stimulated Gene Restricts Mammalian Reovirus Infection.

Alexandra Doms, Tatiana Sanabria, Jeanne N Hansen, Nihal Altan-Bonnet, Geoffrey H Holm

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of virology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Advances on genetic and genomic studies of ALV resistance.Journal of animal science and biotechnology · 2022
    Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Cholesterol 25-hydroxylase suppresses SARS-CoV-2 replication by blocking membrane fusion.Proceedings of the National Academy of Sciences of the United States of America · 2020
    Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Alexandra DomsDepartment of Biology, Colgate University, Hamilton, New York, USA.
Tatiana SanabriaDepartment of Biology, Colgate University, Hamilton, New York, USA.
Jeanne N HansenDepartment of Biology, Colgate University, Hamilton, New York, USA.
Nihal Altan-BonnetLaboratory of Host-Pathogen Dynamics, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.
Geoffrey H HolmDepartment of Biology, Colgate University, Hamilton, New York, USA gholm@colgate.edu.ORCID https://orcid.org/0000-0002-7077-1375

Funding

Virus Egress PathwaysZIAHL006234 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI ALTAN-BONNET, NIHAL · 2017 to 2025
$21.8M
Mechanisms and Functional Consequences of Reovirus Innate Immune ActivationR15AI094440 · NIAID · COLGATE UNIVERSITY · PI HOLM, GEOFFREY H · 2011 to 2015
$740k
NIAID NIH HHS R15 AI094440
6 · The paper itself

Abstract

Following the initial detection of viral infection, innate immune responses trigger the induction of numerous interferon-stimulated genes (ISGs) to inhibit virus replication and dissemination. One such ISG encodes cholesterol-25-hydroxylase (CH25H), an enzyme that catalyzes the oxidation of cholesterol to form a soluble product, 25-hydroxycholesterol (25HC). Recent studies have found that CH25H is broadly antiviral; it inhibits infection by several viruses. For enveloped viruses, 25HC inhibits membrane fusion, likely by altering membrane characteristics such as hydrophobicity or cholesterol aggregation. However, the mechanisms by which 25HC restricts infection of nonenveloped viruses are unknown. We examined whether 25HC restricts infection by mammalian reovirus. Treatment with 25HC restricted infection by reovirus prototype strains type 1 Lang and type 3 Dearing. In contrast to reovirus virions, 25HC did not restrict infection by reovirus infectious subvirion particles (ISVPs), which can penetrate either directly at the cell surface or in early endosomal membranes. Treatment with 25HC altered trafficking of reovirus particles to late endosomes and delayed the kinetics of reovirus uncoating. These results suggest that 25HC inhibits the efficiency of cellular entry of reovirus virions, which may require specific endosomal membrane dynamics for efficient membrane penetration.

Indexed as

AnimalsAntiviral AgentsCell LineHeLa CellsHumansHydroxycholesterolsImmunity, InnateInterferon Type IReoviridaeSteroid HydroxylasesVirionVirus InternalizationVirus Replication25-hydroxycholesterolAntiviral Agentscholesterol 25-hydroxylaseHydroxycholesterolsInterferon Type ISteroid Hydroxylases25-hydroxycholesterolcholesterol-25-hydroxylaseinterferonreovirus

Identifiers

PMID29950420
PMCPMC6146694

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.